CAL
CELG

Capital Analysts LLC’s Celgene Corp CELG Stock Holding History

Capital Analysts LLC’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-400
Closed -$39K – 749
2019
Q3 		$39K Sell
400
-667
-63% -$63.4K ﹤0.01% 417
2019
Q2 		$99K Buy
1,067
+328
+44% +$31.1K 0.01% 277
2019
Q1 		$69K Sell
739
-178
-19% -$15.6K 0.01% 309
2018
Q4 		$59K Sell
917
-12
-1% -$886 0.01% 300
2018
Q3 		$83K Buy
929
+116
+14% +$10.3K 0.01% 257
2018
Q2 		$65K Buy
813
+250
+44% +$20.8K 0.01% 300
2018
Q1 		$50K Buy
563
+115
+26% +$11K 0.01% 310
2017
Q4 		$47K Sell
448
-55
-11% -$6.21K 0.01% 319
2017
Q3 		$73K Buy
503
+144
+40% +$19.6K 0.01% 276
2017
Q2 		$46.6K Buy
359
+90
+33% +$11K 0.01% 312
2017
Q1 		$33.5K Buy
+269
New +$32.2K 0.01% 289

Other funds holding CELG

FP
Factorial Partners Mt. Kisco, New York $138M AUM 25.59% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

Capital Analysts LLC's CELG Position: Q4 2019 in Review

Capital Analysts LLC sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 400 shares — an estimated $39K sold.

Capital Analysts LLC first reported a position in CELG in Q1 2017 and held it in 11 quarters. The position peaked at $99K in Q2 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Capital Analysts LLC reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Capital Analysts LLC sold 400 Celgene Corp shares in Q4 2019, an estimated $39K.
  • Capital Analysts LLC first reported a position in Celgene Corp in Q1 2017 and held it in 11 quarters.
  • Capital Analysts LLC's Celgene Corp position peaked at $99K in Q2 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Capital Analysts LLC's 13F filing for Q4 2019, filed 12 Feb 2020.